









Markets
/
Stocks
/
nasdaq-phvs
/

Pharvaris NV

PHVS



View Detailed Chart

21.690USD

+0.730+3.48%

Market hours （ET）Quotes delayed by 15 min

1.19BMarket Cap

LossP/E TTM



Pharvaris NV

21.690

+0.730+3.48%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+3.48%

5 Days

-3.34%

1 Month

-6.51%

6 Months

+71.87%

Year to Date

+13.15%

1 Year

+5.50%

View Detailed Chart

TradingKey Stock Score of Pharvaris NV

Currency: USD Updated: 2025-10-14

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pharvaris NV's Score

Industry at a Glance

Industry Ranking

235 / 501

Overall Ranking

403 / 4694

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

34.455

Target Price

+56.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pharvaris NV Highlights

StrengthsRisks

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -8.96, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.75M shares, decreasing 3.62% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 3.65M shares of this stock.